<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05123287</url>
  </required_header>
  <id_info>
    <org_study_id>2019-221</org_study_id>
    <nct_id>NCT05123287</nct_id>
  </id_info>
  <brief_title>A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up</brief_title>
  <official_title>A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb&#xD;
      Treated Tumor Patients by Artery Ultrasound Follow-up&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a perspective, self-controlled cohort study. This study aims to evaluate the&#xD;
      effectiveness of anti-PD-1 mAbs (PD-1 immune checkpoint blockades) on atherosclerotic carotid&#xD;
      plaques in those anti-PD-1 mAbs treated patients. The method for quantification and&#xD;
      evaluation of atherosclerotic plaques are based on the: ① The mean intima-media thickness of&#xD;
      the common carotid artery (Mean CCA thickness); ② The maximum intima-media thickness of the&#xD;
      internal carotid artery (maximum ICA thickness); ③ Carotid plaque burden: by calculation of&#xD;
      the plaque area of atherosclerotic plaques on the long axis direction of artery on the&#xD;
      ultrasound images. By comparing the above-mentioned parameters at the same location of&#xD;
      carotid artery in each patient when initiate the first-dose of anti-PD-1 mAbs therapy and 3&#xD;
      months post anti-PD-1 mAbs therapy. It is designed to assess the effectiveness of anti-PD-1&#xD;
      mAbs on the progression of carotid plaques.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>The mean intima-media thickness of the common carotid artery</measure>
    <time_frame>3 months</time_frame>
    <description>It was measured over a segment of the common carotid artery that was 1 cm long, located approximately 0.5 cm below the carotid-artery bulb, and considered not to contain any plaque (i.e., not to have any perceivable protrusion of the artery wall into the lumen).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum intima-media thickness of the internal carotid artery</measure>
    <time_frame>3 months</time_frame>
    <description>It was defined as the greatest intima-media thickness in either the right or left internal carotid artery extending from the bulb to 1 cm above the carotid sinus, ascertained from a total of four views on each side.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carotid plaque burden</measure>
    <time_frame>3 months</time_frame>
    <description>Carotid plaque area measured by ultrasound (cross-sectional area of longitudinal views of all plaques seen) to quantify the increase or decrease of atherosclerotic carotid plaques.</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Plaque, Atherosclerotic</condition>
  <condition>Immune Checkpoint Inhibitors</condition>
  <condition>Programmed Cell Death Protein 1 Inhibitor</condition>
  <condition>Carotid Artery Plaque</condition>
  <condition>Intimal Medial Thickness of Internal Carotid Artery</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 immune checkpoint blockades</intervention_name>
    <description>intravenous injection; frequency: 2-3 weeks/cycle; duration: 3 months</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study population are the PD-1 immune checkpoint blockade treated tumor patients from 2nd&#xD;
        Affiliated Hospital, School of Medicine, Zhejiang University, China.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The age of subjects are between 18-90 years old (including 18 and 90 years old);&#xD;
&#xD;
          2. All kinds of tumor diseases of subjects are acceptable;&#xD;
&#xD;
          3. All kinds of PD-1 immune checkpoint blockades or dosages are acceptable;&#xD;
&#xD;
          4. The subjects knew about the experiment and signed the informed consent voluntarily;&#xD;
&#xD;
          5. The subjects plan to receive PD-1 immune checkpoint blockades and potentially to be&#xD;
             treated for over 3 months;&#xD;
&#xD;
          6. The subjects complicated with atherosclerotic carotid plaques.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects stop receiving or changing the PD-1 immune checkpoint blockades during&#xD;
             follow-up;&#xD;
&#xD;
          2. Subjects are reluctant to continue to be involved in this study;&#xD;
&#xD;
          3. Known pregnant and lactating women;&#xD;
&#xD;
          4. The parameters (e.g., CCA intima-media, ICA intima-media or carotid plaque burden)&#xD;
             could not be calculated because of the quality of ultrasound image;&#xD;
&#xD;
          5. Other situations that the researchers judged were not suitable for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jianan Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Affiliated Hospital, School of Medicine at Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianan Wang, MD, PhD</last_name>
    <phone>+86 0571 87784808</phone>
    <email>wangjianan111@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lin Fan, PhD</last_name>
    <phone>+86 13656691938</phone>
    <email>fanlin@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University, School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Fan, PhD</last_name>
      <phone>86-13656691938</phone>
      <email>fanlin@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Spence JD. Measurement of carotid plaque burden. JAMA Neurol. 2015 Apr;72(4):383-4. doi: 10.1001/jamaneurol.2014.3002. Review.</citation>
    <PMID>25686472</PMID>
  </reference>
  <reference>
    <citation>O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999 Jan 7;340(1):14-22.</citation>
    <PMID>9878640</PMID>
  </reference>
  <results_reference>
    <citation>Spence JD, Eliasziw M, DiCicco M, Hackam DG, Galil R, Lohmann T. Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke. 2002 Dec;33(12):2916-22.</citation>
    <PMID>12468791</PMID>
  </results_reference>
  <results_reference>
    <citation>Lorenz MW, Polak JF, Kavousi M, Mathiesen EB, Völzke H, Tuomainen TP, Sander D, Plichart M, Catapano AL, Robertson CM, Kiechl S, Rundek T, Desvarieux M, Lind L, Schmid C, DasMahapatra P, Gao L, Ziegelbauer K, Bots ML, Thompson SG; PROG-IMT Study Group. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet. 2012 Jun 2;379(9831):2053-62. doi: 10.1016/S0140-6736(12)60441-3. Epub 2012 Apr 27. Erratum in: Lancet. 2012 Aug 4;380(9840):474.</citation>
    <PMID>22541275</PMID>
  </results_reference>
  <results_reference>
    <citation>Polak JF, Pencina MJ, Pencina KM, O'Donnell CJ, Wolf PA, D'Agostino RB Sr. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med. 2011 Jul 21;365(3):213-21. doi: 10.1056/NEJMoa1012592.</citation>
    <PMID>21774709</PMID>
  </results_reference>
  <results_reference>
    <citation>Saba L, Saam T, Jäger HR, Yuan C, Hatsukami TS, Saloner D, Wasserman BA, Bonati LH, Wintermark M. Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications. Lancet Neurol. 2019 Jun;18(6):559-572. doi: 10.1016/S1474-4422(19)30035-3. Epub 2019 Apr 4. Review.</citation>
    <PMID>30954372</PMID>
  </results_reference>
  <results_reference>
    <citation>Lechareas S, Yanni AE, Golemati S, Chatziioannou A, Perrea D. Ultrasound and Biochemical Diagnostic Tools for the Characterization of Vulnerable Carotid Atherosclerotic Plaque. Ultrasound Med Biol. 2016 Jan;42(1):31-43. doi: 10.1016/j.ultrasmedbio.2015.09.003. Epub 2015 Oct 20. Review.</citation>
    <PMID>26493239</PMID>
  </results_reference>
  <results_reference>
    <citation>Sakaguchi M, Kitagawa K, Nagai Y, Yamagami H, Kondo K, Matsushita K, Oku N, Hougaku H, Ohtsuki T, Masuyama T, Matsumoto M, Hori M. Equivalence of plaque score and intima-media thickness of carotid ultrasonography for predicting severe coronary artery lesion. Ultrasound Med Biol. 2003 Mar;29(3):367-71.</citation>
    <PMID>12706187</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

